TORS Investigators – Team 3

In Vivo Intermediary Metabolism

Lead Investigator

Craig Malloy, M.D., Professor at the Advanced Imaging Research Center, Internal Medicine, and Radiology, directs an NIH Resource Center to develop novel NMR methods for the analysis of metabolism in mice and humans. He was the first investigator to use deuterium NMR to make metabolic measurements in vivo.

Associate Investigators

Jeffrey Browning, M.D., is an Associate Professor in Digestive and Liver Diseases and a recipient of a 2003 Postdoctoral Fellowship from the American Liver Foundation. He performed the largest epidemiological study on the prevalence of hepatic steatosis in the U.S.

Shawn Burgess, Ph.D., an Associate Professor in the Advanced Imaging Research Center and Pharmacology, developed methods at UT Southwestern to use deuterium and carbon-13 NMR for in vivo measurement of gluconeogenesis.

Elizabeth Parks, Ph.D., former Associate Professor of Internal Medicine and the Center for Human Nutrition. Dr. Parks uses stable isotopes and mass spectrometry to characterized metabolic fluxes in humans and mice. Her work was the first to determine the source of fatty acids that accumulate in hepatic steatosis and to demonstrate the importance of liver lipid synthesis in the pathogenesis of fatty liver.

Robert D. Phair, Ph.D., Founder, Chief Scientific Officer, Integrative BioInformatics, Inc., Los Altos, California.

David W. Russell, Ph.D., is a a member of the U.S. National Academy of Sciences (2006) and Professor of Molecular Genetics. He has cloned more than 20 genes involved in bile acid and sterol metabolism. He is an investigator in the NIH-funded LIPIDMAPS consortium, whose goal is to quantify all of the lipids in a living cell. Dr. Russell is the recipient of the Oppenheimer Award from the Endocrinology Society and the Adolph Windaus Prize from the Falk Foundation.

Dean Sherry, Ph.D., is a Professor of Chemistry at the University of Texas at Dallas and is the Director of the Advanced Imaging Research Center at UTSW. Dr. Sherry developed novel and sensitive macrocyclics for use as NMR molecular imaging agents.